U.S. auto retail faces volume pressure and eroding purchasing power. Yet LAD and SAH stand out with smart acquisitions, digital push and shareholder returns.
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
MEDFORD, Ore., May 26, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) announced today an increase to its share repurchase authorization of $500 million to bring the current remaining authorization to $726 million.
Although the revenue and EPS for Lithia Motors (LAD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.